Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
LIBOURNE, France and DURHAM, N.C., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Ceva Santé Animale and Zoion Pharma Inc. announced today that they have entered into a collaboration to develop an epithelial sodium channel (ENaC) inhibitor to treat veterinary ocular surface diseases characterized by a lack of surface hydration, such as keratoconjunctivitis sicca (KCS) commonly called dry eye. Under the agreement, Ceva gains worldwide development and commercial rights to ZP-1 (P-1046). ZP-1 has successfully completed a proof-of-concept clinical trial in canine KCS. ZP-1 (P-1046) was originally discovered by Parion Sciences, Inc. and licensed to Zoion Pharma for veterinary use.
|
|||||||||
“KCS is a disease that causes much pain and discomfort, particularly in dogs. If left untreated, severe cases may lead to blindness,” said Jon Alšėnas DVM, President and CEO of Zoion Pharma. “Ceva is the ideal partner to bring this potentially very exciting new therapy to companion animals and their owners around the world.”
Financial terms of the collaboration were not disclosed.
About Ceva Santé Animale:
Ceva Santé Animale was founded in 1999 and is a global veterinary health company, focused on research, development, production and marketing of pharmaceutical products and vaccines for companion animals, livestock, swine and poultry. Its headquarters are in Libourne, France.
About Zoion Pharma:
Zoion Pharma is dedicated to the goal of identifying, sourcing and developing novel or overlooked drugs specifically for use in the treatment of companion animal diseases of high unmet medical need.
About Parion Sciences:
Parion Sciences is a development stage biopharmaceutical company dedicated to research, development and commercialization of treatments to improve and extend the lives of patients with innate mucosal surface defense deficiencies of the lung or eye. Parion has a diverse pipeline of pre-clinical and clinical candidates for the treatment of these diseases via distinctive mechanisms of action and approaches. Parion is at the forefront of ENaC development and leverages its scientific expertise in epithelial biology to expand the company’s platforms and novel chemical compounds into new potential indications to treat mucosal defects.
CONTACT: Jon Alsenas [email protected]
